This HTML5 document contains 165 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/mesh/concept/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/chebi/
n30http://linked.opendata.cz/resource/drugbank/mixture/
n32http://bio2rdf.org/drugbank:
n29http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/kegg-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/pdb/
n28http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/pubchem-substance/
n15http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n31http://www.drugs.com/cdi/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/kegg-drug/
n21http://www.rxlist.com/cgi/generic2/
n9http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00951/identifier/national-drug-code-directory/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00951
rdf:type
n3:Drug
n3:description
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]
n3:dosage
n23:271B415F-363D-11E5-9242-09173F13E4C5 n23:271B4160-363D-11E5-9242-09173F13E4C5 n23:271B4161-363D-11E5-9242-09173F13E4C5 n23:271B4162-363D-11E5-9242-09173F13E4C5 n23:271B4163-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Fast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.
n3:indication
For the treatment of all forms of tuberculosis in which organisms are susceptible.
n3:manufacturer
n4:271B4156-363D-11E5-9242-09173F13E4C5 n4:271B4157-363D-11E5-9242-09173F13E4C5 n4:271B414C-363D-11E5-9242-09173F13E4C5 n4:271B414D-363D-11E5-9242-09173F13E4C5 n4:271B4154-363D-11E5-9242-09173F13E4C5 n4:271B4152-363D-11E5-9242-09173F13E4C5 n4:271B4153-363D-11E5-9242-09173F13E4C5 n4:271B4150-363D-11E5-9242-09173F13E4C5 n4:271B4151-363D-11E5-9242-09173F13E4C5 n4:271B414E-363D-11E5-9242-09173F13E4C5 n4:271B414F-363D-11E5-9242-09173F13E4C5 n4:271B4146-363D-11E5-9242-09173F13E4C5 n4:271B4144-363D-11E5-9242-09173F13E4C5 n4:271B4145-363D-11E5-9242-09173F13E4C5 n4:271B4142-363D-11E5-9242-09173F13E4C5 n4:271B4143-363D-11E5-9242-09173F13E4C5 n4:271B414B-363D-11E5-9242-09173F13E4C5 n4:271B4140-363D-11E5-9242-09173F13E4C5 n4:271B4155-363D-11E5-9242-09173F13E4C5 n4:271B4141-363D-11E5-9242-09173F13E4C5 n4:271B4149-363D-11E5-9242-09173F13E4C5 n4:271B413E-363D-11E5-9242-09173F13E4C5 n4:271B414A-363D-11E5-9242-09173F13E4C5 n4:271B413F-363D-11E5-9242-09173F13E4C5 n4:271B4147-363D-11E5-9242-09173F13E4C5 n4:271B4148-363D-11E5-9242-09173F13E4C5 n4:271B413C-363D-11E5-9242-09173F13E4C5 n4:271B413D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00951 n32:DB00951
dcterms:title
Isoniazid
adms:identifier
n6:46506039 n7:PA450112 n8:3767 n10:0555-0066-02 n11:ISZ n12:C07054 n13:D00346 n14:DB00951 n17:6030 n18:3635 n29:Isoniazid
n3:mechanismOfAction
Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from <i>Mycobacterium tuberculosis</i>, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.
n3:packager
n4:271B411E-363D-11E5-9242-09173F13E4C5 n4:271B411B-363D-11E5-9242-09173F13E4C5 n4:271B411C-363D-11E5-9242-09173F13E4C5 n4:271B4137-363D-11E5-9242-09173F13E4C5 n4:271B4139-363D-11E5-9242-09173F13E4C5 n4:271B4138-363D-11E5-9242-09173F13E4C5 n4:271B413A-363D-11E5-9242-09173F13E4C5 n4:271B413B-363D-11E5-9242-09173F13E4C5 n4:271B4118-363D-11E5-9242-09173F13E4C5 n4:271B412A-363D-11E5-9242-09173F13E4C5 n4:271B412B-363D-11E5-9242-09173F13E4C5 n4:271B4122-363D-11E5-9242-09173F13E4C5 n4:271B4123-363D-11E5-9242-09173F13E4C5 n4:271B4135-363D-11E5-9242-09173F13E4C5 n4:271B4136-363D-11E5-9242-09173F13E4C5 n4:271B412C-363D-11E5-9242-09173F13E4C5 n4:271B4134-363D-11E5-9242-09173F13E4C5 n4:271B4121-363D-11E5-9242-09173F13E4C5 n4:271B4124-363D-11E5-9242-09173F13E4C5 n4:271B411F-363D-11E5-9242-09173F13E4C5 n4:271B4120-363D-11E5-9242-09173F13E4C5 n4:271B4127-363D-11E5-9242-09173F13E4C5 n4:271B4128-363D-11E5-9242-09173F13E4C5 n4:271B4125-363D-11E5-9242-09173F13E4C5 n4:271B4126-363D-11E5-9242-09173F13E4C5 n4:271B412E-363D-11E5-9242-09173F13E4C5 n4:271B412F-363D-11E5-9242-09173F13E4C5 n4:271B4129-363D-11E5-9242-09173F13E4C5 n4:271B412D-363D-11E5-9242-09173F13E4C5 n4:271B4132-363D-11E5-9242-09173F13E4C5 n4:271B4133-363D-11E5-9242-09173F13E4C5 n4:271B4130-363D-11E5-9242-09173F13E4C5 n4:271B4131-363D-11E5-9242-09173F13E4C5 n4:271B4114-363D-11E5-9242-09173F13E4C5 n4:271B4115-363D-11E5-9242-09173F13E4C5 n4:271B4113-363D-11E5-9242-09173F13E4C5 n4:271B4119-363D-11E5-9242-09173F13E4C5 n4:271B411A-363D-11E5-9242-09173F13E4C5 n4:271B4116-363D-11E5-9242-09173F13E4C5 n4:271B4117-363D-11E5-9242-09173F13E4C5 n4:271B411D-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
From 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.
n3:synonym
INH Isoniazid Isonicotinohydrazide Isonicotinoylhydrazide Pyridine-4-carboxylic acid hydrazide Isonicotinic acid hydrazide Isonicotinylhydrazine Isonicotinsaeurehydrazid 4-pyridinecarbohydrazide Isonicotinic hydrazide
n3:toxicity
LD<sub>50</sub> 100 mg/kg (Human, oral). Adverse reactions include rash, abnormal liver function tests, hepatitis, peripheral neuropathy, mild central nervous system (CNS) effects. In vivo, Isoniazid reacts with pyridoxal to form a hydrazone, and thus inhibits generation of pyridoxal phosphate. Isoniazid also combines with pyridoxal phosphate; high doses interfere with the coenzyme function of the latter.
n24:hasAHFSCode
n26:08-16-04
n3:foodInteraction
Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication. Avoid alcohol. Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin. Take on empty stomach: 1 hour before or 2 hours after meals. Take with a full glass of water. Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
n3:mixture
n30:271B4111-363D-11E5-9242-09173F13E4C5 n30:271B4112-363D-11E5-9242-09173F13E4C5 n30:271B4110-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Very low (0-10%)
n3:synthesisReference
Costin Rentzea, Albrecht Harreus, Eberhard Ammermann, Gisela Lorenz, "Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides." U.S. Patent US5399589, issued November, 1969.
n15:hasConcept
n16:M0011772
foaf:page
n21:isoniaz.htm n31:isoniazid.html
n3:IUPAC-Name
n9:271B4168-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B416E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B416D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B416A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B416B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B416C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B417E-363D-11E5-9242-09173F13E4C5 n9:271B4166-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B4180-363D-11E5-9242-09173F13E4C5 n9:271B4167-363D-11E5-9242-09173F13E4C5 n9:271B4164-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B4181-363D-11E5-9242-09173F13E4C5 n9:271B4165-363D-11E5-9242-09173F13E4C5
n3:pKa
n9:271B4182-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:J04AC01
n3:H-Bond-Acceptor-Count
n9:271B4174-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B4175-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B416F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B4170-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B4172-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B4171-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B4173-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.
n3:affectedOrganism
Mycobacteria Mycobacterium tuberculosis
n3:casRegistryNumber
54-85-3
n3:category
n3:containedIn
n19:271B4158-363D-11E5-9242-09173F13E4C5 n19:271B415B-363D-11E5-9242-09173F13E4C5 n19:271B415C-363D-11E5-9242-09173F13E4C5 n19:271B4159-363D-11E5-9242-09173F13E4C5 n19:271B415A-363D-11E5-9242-09173F13E4C5 n19:271B415D-363D-11E5-9242-09173F13E4C5 n19:271B415E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B417A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B417C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B417D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B417F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B4179-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B4178-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B417B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B4169-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B4176-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B4177-363D-11E5-9242-09173F13E4C5